Home » Health Policy » Pharmaceutical Policy and Regulation

Category Archives: Pharmaceutical Policy and Regulation

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them. (more…)

Value-based drug pricing makes sense, but is difficult to pull off

Dana Goldman and Anupam Jena discuss the challenges of value-based pricing and health technology assessments. (more…)

Value-Based Pricing For Pharmaceuticals In The Trump Administration

The change in administration is an opportune moment for CMS to assume a leadership role with respect to value-based pricing.  (more…)

A Good Deal For Eliminating Hepatitis C: Saving Money And Lives

Hepatitis C kills more than 20,000 Americans each year. A recent consensus committee of the National Academies of Sciences, Engineering, and Medicine proposed a novel strategy to improve access to hepatitis C medicines. (more…)

How Expanding the Role of Pharmacists Lowered Readmissions and Costs in one California Community

Technology and data can help pharmacists provide services required to manage life-long, outpatient drug therapies. (more…)

Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform

The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement. (more…)

Why Academics Consulting with Industry on Health Care May be an Idea Whose Time has Come

At a time of deep political division, an academic approach to policy making has never been more important. (more…)

Election verdict: Pharma Needs a New Prescription

Dana Goldman and Darius Lakdawalla provide a policy prescription list for the pharmaceutical industry aimed at improving access for patients today without discouraging investments into tomorrow’s medical innovations.  (more…)

Encouraging Integrative, Non-Opioid Approaches To Pain: A Policy Agenda

National initiatives are underway to dramatically reduce access to prescription opioids, but these efforts lack a systematic approach to provide alternative treatments for these patients. Jason Doctor and his colleagues outline three feasible policy initiatives.  (more…)

To Prevent Another EpiPen Controversy, the Government Should Step In

The real problem is with lax regulatory oversight that doesn’t ensure an adequate supply of drugs critical to population health and opens the door to shocking price increases.  (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook